scholarly journals Developing Population Pharmacokinetic Parameters for High-Dose Methotrexate Therapy: Implication of Correlations among Developed Parameters for Individual Parameter Estimation Using the Bayesian Least-Squares Method

2014 ◽  
Vol 37 (6) ◽  
pp. 916-921 ◽  
Author(s):  
Masahiro Watanabe ◽  
Noriyasu Fukuoka ◽  
Toshiki Takeuchi ◽  
Kazunori Yamaguchi ◽  
Takahiro Motoki ◽  
...  
2002 ◽  
Vol 36 (9) ◽  
pp. 1344-1350 ◽  
Author(s):  
Irene Aquerreta ◽  
Azucena Aldaz ◽  
Joaquín Giráldez ◽  
Luis Sierrasesúmaga

OBJECTIVE: To establish a relationship between the pharmacokinetics of high-dose methotrexate (MTX) and toxicity in children of a pediatric oncology department and to reassess MTX concentrations at which the patients would be at high risk for toxic effects. METHODS: This study included 37 patients (227 treatment courses) who received a median dose of 4.87 g/m2 of MTX in a 4-hour infusion. The population pharmacokinetic parameters of MTX were estimated by parametric (IT2B) and nonparametric methods (NPEM). Gastrointestinal, renal, and hematologic toxicity were evaluated. The relationship between pharmacokinetic parameters and toxicity was analyzed by logistic regression and multiple linear regression. RESULTS: Equations to predict hematologic and nonhematologic toxicity were obtained. An increase of 100 μmol/L in the MTX peak concentration meant a 12% (p = 0.03) higher risk of vomiting; a significant delay in MTX elimination implied a 5.76-fold higher risk of mucositis (p < 0.001). An increase of 1 μmol/L in the MTX concentration 24 hours after the end of the infusion (Cp24h) led to a 43% increase in the risk of renal toxicity (p < 0.001). Hematologic toxicity was significantly conditioned by the baseline leukocyte count and Cp24h (p < 0.001). CONCLUSIONS: The analysis of high-dose MTX pharmacokinetic/pharmacodynamic relationship to toxicity has led to equations able to predict toxicity that are easily applicable to daily practice. Cp24h >3.5 μmol/L was confirmed as an indicator of high risk of toxicity.


Rheumatology ◽  
1988 ◽  
Vol 27 (2) ◽  
pp. 160-162 ◽  
Author(s):  
E. EECKHOUT ◽  
E. SUYS ◽  
P. BUYDENS ◽  
S. VAN BELLE ◽  
L. A. VERBRUGGEN

2008 ◽  
Vol 30 (12) ◽  
pp. 950-952 ◽  
Author(s):  
Theodore Scott Nowicki ◽  
Kari Bjornard ◽  
David Kudlowitz ◽  
Claudio Sandoval ◽  
Somasundaram Jayabose

1995 ◽  
Vol 24 (2) ◽  
pp. 137-140 ◽  
Author(s):  
Zakiya Al-Lamki ◽  
Eileen Thomas ◽  
Nagwa El-Banna ◽  
Norman Jaffe

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Darragh O'Donoghue ◽  
Heather Truong ◽  
Heidi Finnes ◽  
Jennifer McDonald ◽  
Nelson Leung

Abstract Background and Aims High dose Methotrexate (HDMTX) is an important component of several modern oncological/haematological treatment protocols due to its central nervous system penetrance. Nephrotoxicity represents a significant adverse effect and can limit therapeutic options. Therefore, strategies to prevent this are paramount. Urinary alkalinisation and large volume resuscitation to maintain adequate hydration and urine output are the typical strategies. Urinary alkalinisation prevents tubular precipitation of methotrexate and therefore, a strict urinary pH target of 7 is maintained via a continuous bicarbonate infusion. Method We describe a case report, of Iatrogenic metabolic alkalosis leading to respiratory compromise in a patient receiving HDMTX from Mayo Clinic, Rochester. Results We present the case of a 76-year-old woman with a Diffuse Large B-Cell Lymphoma with CNS involvement who presented for elective admission for her 1st cycle of HDMTX. She received 7g of Methotrexate at dosing of 8 g/m2. She received the standard urinary alkalinisation with pre- and post-hydration. Her baseline HCO3- was 28 mEq/L. Her 48 hour MTX level was elevated at 1.2 so the urinary alkalinisation protocol was continued until &lt;0.1 mcmol/L. On day 4, she developed frequent episodes of apnoea. Her ABG demonstrated a metabolic alkalaemia pH 7.54, pCO 53, pO2 91, HCO3 45. She was transferred to the ICU for close monitoring. Her bicarbonate infusion was discontinued and she received acetazolamide. Her bicarbonate improved to 31 after 12 hours. She had a significant improvement in her respiratory status with no further episodes of apnoea. Her bicarbonate infusion was restarted due to elevated MTX levels. She was discharged home with no further complications. Conclusion Iatrogenic Metabolic alkalosis leading to respiratory compromise represents a rare but important complication of urinary alkalinsation protocols for High-dose Methotrexate therapy.


1998 ◽  
Vol 44 (9) ◽  
pp. 1987-1989 ◽  
Author(s):  
Anne Berit Guttormsen ◽  
Per Magne Ueland ◽  
Per Eystein Lønning ◽  
Olav Mella ◽  
Helga Refsum

Sign in / Sign up

Export Citation Format

Share Document